ABT: Symmetrical Triangle detected on 25 Jun 2026

ABT is forming a symmetrical triangle with strong structural integrity (score: 13.0/15) on solid breakout conviction (12.0/13), though volume support is moderate at 7.0/12. The pattern is constricting between support at $87.86 and resistance at $90.86, with price currently at $90.49—near the upper band. The triangle sits within a bullish market regime (0.93 score) and suggests a breakout target of $94.59 (conservative measure). RSI at 54.21 indicates balanced momentum, neither overbought nor oversold, supporting continuation potential.

Abbott faces a 29% year-to-date decline despite strong revenue growth and solid dividend history, yet the stock is down 30.6% YTD due to reduced earnings guidance and competitive pressures. Catalysts are mounting: Abbott received FDA clearance for Ultreon 3.0, its next-generation AI-powered coronary imaging platform, on April 28, 2026, and showcased 11 cancer diagnostics abstracts at ASCO 2026 in May-June. Libre Duo and Libre Duo 10 Day, dual glucose-ketone sensors, obtained CE Mark in May 2026 and are pending FDA clearance. Full-year 2026 guidance projects 6.5–7.5% comparable sales growth and adjusted EPS of $5.38–$5.58. Wells Fargo reaffirmed a Buy rating with analysts seeing accelerating 2027 earnings and maintaining a $120 price target on Libre Duo growth potential.

A successful breakout above $90.86 resistance would target the conservative measure of $94.59, representing ~4.5% upside. The measured move derives from the triangle's height applied to the breakout point. Volume confirmation is essential—breakout should show expanding volume relative to the 0.93 recent ratio to validate conviction. The setup fails and reverses if price closes below key support at $87.86, which would invalidate the pattern. The 60.04% historical win probability indicates better-than-even odds, though the moderate 69.0 overall score reflects some structural limitations—particularly the 7.0/12 volume score suggesting insufficient accumulation confirmation.

The stock has faced reduced earnings guidance and competitive pressures, and Q1/26 saw operating income and EPS decline year-over-year despite revenue growth; the $21B Exact Sciences acquisition increases debt and will dilute EPS for two years. An earnings report is scheduled for July 16, 2026—near-term volatility risk. High goodwill and elevated debt warrant caution on capital returns. Low beta (0.47) mitigates systematic risk, but the stock's 33.6% underperformance versus 52-week highs and down 12.5% over three months suggests persistent headwinds despite dividend and growth catalysts. Sector regime is weak (0.37 score), indicating healthcare underperformance relative to broad market.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.